Abstract:
Colorectal cancer (CRC) is an abnormal growth in the lining of the colon and
rectum. The early abnormal growth of CRC is called precancerous Polyps. If left
untreated the uncontrolled growth turns into mature Polyps. The most common type
of CRC is adenocarcinomas which usually occur in the mucus-producing cells in the
inner layer of colon. Carcinoid tumors, gastrointestinal stromal tumors and sarcomas
are the other types of colorectal cancer. The main symptoms of CRC are diarrhea, dis-
comfort in the abdomen, anemia and fatigue. Age, race, gender, and a person’s family
history are the main risk factors in developing colorectal cancer. Various therapies pre-
viously available to treat colorectal cancer includes chemotherapy, radiation therapy
and targeted therapy. All these existing therapies have some after-effects therefore,
there is a need to develop an effective therapy for the treatment of colorectal cancer.
In this research, we performed microarray and RNA-seq analysis to get differentially
expressed genes of colorectal cancer. For this purpose, we used three Microarray and
one RNA sequencing dataset that were obtained from publicly available databases.
After getting DEGs we used David (The Database for Annotation, Visualization, and
Integrated Discovery) tool to find out which differentially expressed genes are highly
associated with colorectal cancer.AURKA gene from David tool was selected for
further analysis. According to literature, AURKA gene is upregulated in colorectal
cancer and overexpression of this gene causes CRC cell progression and proliferation.
Furthermore, we performed the docking of Auorora Kinase A (AURKA) protein with
220 FDA-approved anticancer drugs that were chosen as ligands. The anti-cancer
drugs such as Dactinomycin, Dutasteride, Lumacaftor, Alectinib, Daridorexan, Can-
desartan, Tonabersat, Ziconotide, Camptothecin, and Diamorphine show excellect
binding interactions with Auorora Kinase A protein.
